Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CHMP6 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q96FZ7 |
|---|---|
| Clone Names | 100324055 |
| Gene ID | 79643 |
|---|---|
| Other Names | Charged multivesicular body protein 6, Chromatin-modifying protein 6, Vacuolar protein sorting-associated protein 20, Vps20, hVps20, CHMP6, VPS20 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | CHMP6 |
|---|---|
| Synonyms | VPS20 |
| Function | Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. In the ESCRT-III complex, it probably serves as an acceptor for the ESCRT-II complex on endosomal membranes. |
| Cellular Location | Endomembrane system. Endosome membrane; Lipid- anchor. Late endosome membrane. Membrane; Lipid-anchor. Note=Localizes to endosomal membranes |
| Tissue Location | Ubiquitously expressed. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CHMP6 belongs to the chromatin-modifying protein/chargedmultivesicular body protein (CHMP) family. These proteins arecomponents of ESCRT-III (endosomal sorting complex required fortransport III), a complex involved in degradation of surfacereceptor proteins and formation of endocytic multivesicular bodies(MVBs). Some CHMPs have both nuclear and cytoplasmic/vesiculardistributions, and one such CHMP, CHMP1A (MIM 164010), is requiredfor both MVB formation and regulation of cell cycle progression(Tsang et al., 2006 [PubMed 16730941]).
References
Im, Y.J., et al. Dev. Cell 17(2):234-243(2009)Fu, D., et al. Biosci. Biotechnol. Biochem. 73(3):494-501(2009)Kieffer, C., et al. Dev. Cell 15(1):62-73(2008)Lamesch, P., et al. Genomics 89(3):307-315(2007)Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
